Lilly to acquire ARMO BioSciences

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Eli Lilly and Co. and ARMO BioSciences Inc. announced a definitive agreement for Lilly to acquire ARMO for $50 per share, or approximately $1.6 billion, in an all-cash transaction.

To access this subscriber-only content please log in or renew your subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe

YOU MAY BE INTERESTED IN

Login